The role of economic evaluation in vaccine decision making: Focus on meningococcal group C conjugate vaccine

PharmacoEconomics

Volumn 23, Issue 9, 2005, Pages 855-874

  Welte, Robert ^a   Trotter, Caroline L ^b   Edmunds, W John ^b   Postma, Maarten J ^c   Beutels, Philippe ^d,e,f  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^f UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; CHICKENPOX VACCINE; CHLAMYDIA TRACHOMATIS VACCINE; CIPROFLOXACIN; CONJUGATE VACCINE; CYTOMEGALOVIRUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE PLUS MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; RIFAMPICIN; UNCLASSIFIED DRUG; VACCINE; WART VIRUS VACCINE;

AUSTRALIA; CANADA; CHEMOPROPHYLAXIS; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DISEASE TRANSMISSION; DRUG COST; ECONOMIC EVALUATION; HEALTH PROGRAM; HERD IMMUNITY; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; INCIDENCE; LITERATURE; MASS IMMUNIZATION; MEASLES; MEDLINE; MENINGOCOCCOSIS; METHODOLOGY; MUMPS; NEISSERIA MENINGITIDIS; NETHERLANDS; NONHUMAN; PORTUGAL; PRIORITY JOURNAL; PUBLIC HEALTH; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; RUBELLA; SIDE EFFECT; SPAIN; SWITZERLAND; UNITED KINGDOM;

COST-BENEFIT ANALYSIS; DECISION MAKING; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; VACCINATION;

EID: 24944462813     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200523090-00001     Document Type: Review

References (95)

1. Handford S, Ramsay ME, Fox AJ, et al. Invasive Neisseria meningitidis in Europe: 2002. London: European Union Invasive Bacterial Infections Surveillance Network, 2003 [online]. Available from URL: http://www.euibis.org [Accessed 2004 Jul 2]
2. Cohen NJ. Introduction of the national meningococcal C vaccination program. Commun Dis Intell 2003; 27 (2): 161-2
3. De Wals P, De Serres G, Niyonsenga T. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec. JAMA 2001; 285 (2): 177-81
4. Van Deuren M, Brandtzaeg P, van der Meer JW. Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev 2000; 13 (1): 144-66
5. Jodar L, Feavers IM, Salisbury D, et al. Development of vaccines against meningococcal disease. Lancet 2002; 359 (9316): 1499-508
6. Offit PA, Peter G. The meningococcal vaccine: public policy and individual choices. N Engl J Med 2003; 349 (24): 2353-6
7. Pollard AJ, Levin M. Vaccines for prevention of meningococcal disease. Pediatr Infect Dis J 2000; 19 (4): 333-44
8. Saez-Llorens X, McCracken Jr GH. Bacterial meningitis in children. Lancet 2003; 361 (9375): 2139-48
9. Stephens DS, Zimmer SM. Pathogenesis, therapy, and prevention of meningococcal sepsis. Curr Infect Dis Rep 2002; 4 (5): 377-86
10. Annual report of the Australian meningococcal surveillance programme, 1999. Commun Dis Intell 2000; 24 (7): 181-9
11. Annual report of the Australian meningococcal surveillance programme, 2000. Commun Dis Intell 2001; 25 (3): 113-21
12. Annual report of the Australian meningococcal surveillance programme, 2001. Commun Dis Intell 2002; 26 (3): 407-18
13. Annual report of the Australian meningococcal surveillance programme, 2002. Commun Dis Intell 2003; 27 (2): 196-208
14. Handford S, Ramsay ME, Fox AJ, et al. Surveillance network for invasive Neisseria meningitidis in Europe: 1999 & 2000. London: European Union Invasive Bacterial Infections Surveillance Network, 2001 [online]. Available from URL: http://www.euibis.org [Accessed 2003 Oct 20]
15. Handford S, Ramsay ME, Fox AJ, et al. Invasive Neisseria meningitidis in Europe: 2001. London: European Union Invasive Bacterial Infections Surveillance Network, 2003 [online]. Available from URL: http://www.euibis.org [Accessed 2003 Oct 20]
16. Noah N, Henderson B. Surveillance of bacterial meningitis in Europe 1999/2000. London: European Bacterial Meningitis Surveillance Project. PHLS Communicable Disease Surveillance Centre, 2002 Feb
17. Health Canada. Invasive meningococcal disease in Canada, 1 January 1997 to 31 December 1998. Can Commun Dis Rep 2000; 26 (21): 177-82
18. Health Canada. Meningococcal: vaccine preventable diseases. Ottawa (ON): Health Canada, Division of Immunization and Preventable Diseases; 2003 Jan 8
19. Institut national de sante publique du Quebec. Surveillance des infections envahissantes a Neisseria meningitidis. Rapport annuel 2000. Quebec: Institut national de sante publique du Quebec, 2001
20. Institut national de sante publique Quebec. Surveillance des infections envahissantes a Neisseria meningitidis. Rapport annuel 2001. Quebec: Institut national de sante publique du Quebec, 2002
21. De Wals P, Deceuninck G, Boulianne N, et al. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine. JAMA 2004; 292 (20): 2491-4
22. Silverio NM, Brandao JT, Chinopa PF. Cost-effectiveness of two different vaccination strategies for the prevention of meningococcal C disease in Portugal [abstract]. Value Health 2003; 6 (6): 748
23. Bundesamt für Gesundheit. Epi-Notiz: Entwicklung der Meningokokkeninfektionen in der Schweiz: Juli 1999-Juni 2002. Bulletin BAG 2003; 4: 48-50
24. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) report emerging infections program network, Neisseria meningitidis, 2002. Atlanta (GA): Centers for Disease Control and Prevention, 2003
25. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) report emerging infections program network, Neisseria meningitidis, 1999. Atlanta (GA): Centers for Disease Control and Prevention, 2000
26. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) report emerging infections program network, Neisseria meningitidis, 2000. Atlanta (GA): Centers for Disease Control and Prevention, 2002
27. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) report emerging infections program network, Neisseria meningitidis, 2001. Atlanta (GA): Centers for Disease Control and Prevention, 2003
28. Baraff LJ, Lee SI, Schriger DL. Outcomes of bacterial meningitis in children: a meta-analysis. Pediatr Infect Dis J 1993; 12 (5): 389-94
29. Healy CM, Butler KM, Smith EO, et al. Influence of serogroup on the presentation, course, and outcome of invasive meningococcal disease in children in the Republic of Ireland, 1995-2000. Clin Infect Dis 2002; 34 (10): 1323-30
30. Pomeroy SL, Holmes SJ, Dodge PR, et al. Seizures and other neurologic sequelae of bacterial meningitis in children. N Engl J Med 1990; 323 (24): 1651-7
31. Schildkamp RL, Lodder MC, Bijlmer HA, et al. Clinical manifestations and course of meningococcal disease in 562 patients. Scand J Infect Dis 1996; 28 (1): 47-51
32. Trotter CL, Fox AJ, Ramsay ME, et al. Fatal outcome from meningococcal disease: an association with meningococcal phenotype but not with reduced susceptibility to benzylpenicilin. J Med Microbiol 2002; 51 (10): 855-60
33. Erickson L, De Wals P. Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994. Clin Infect Dis 1998; 26 (5): 1159-64
34. Advisory Committee on Immunization Practices. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2000; 49 (RR-7): 1-10
35. Advisory Committee on Immunization Practices. Control and prevention of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 1997; 46 (RR-5): 1-10
36. Bundesamt für Gesundheit. Prävention von invasiven Meningokokkeninfektionen. Empfehlungen der Schweizerischen Kommission für Impffragen, der Arbeitsgruppe Meningokokken und des Bundesamtes für Gesundheit. Bulletin BAG 2001; 46: 893-901
37. Committee on Infectious Diseases American Academy of Pediatrics. Infectious Diseases and Immunization Committee CPS. Meningococcal disease prevention and control strategies for practice-based physicians. Pediatrics 1996; 97 (3): 404-12
38. Landelijke Cöordinatiestructuur Infectieziektenbestrijding. Draaiboek meningokokkenmeningitis en-sepsis. Den Haag: Landelijke Cöordinatiestructuur Infectieziektenbestrijding, 1996 May
39. Robert Koch Institut. Meningokokken-Erkrankungen. In: Ratgeber Infektionskrankheiten - Merkblätter für Ärzte: Robert Koch Institut, 2003
40. World Health Organization. State of the art of new vaccines: research and development. Geneva: World Health Organization, 2003 Apr
41. National Advisory Committee on Immunization. Statement on recommended use of meningococcal vaccines. Can Commun Dis Rep 2001; 27: 2-36
42. Balmer P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol 2002; 51 (9): 717-22
43. Bose A, Coen P, Tully J, et al. Effectiveness of meningococcal C conjugate vaccine in teenagers in England. Lancet 2003; 361 (9358): 675-6
44. Ramsay ME, Andrews N, Kaczmarski EB, et al. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001; 357 (9251): 195-6
45. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001; 20 Suppl. 1: S58-67
46. Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364 (9431): 365-7
47. Snape MD, Kelly DF, Green B, et al. Lack of serum bactericidal activity in pre-school children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr Infect Dis J 2005; 24 (2): 128-31
48. Barbour ML. Conjugate vaccines and the carriage of Haemophilus influenzae type b. Emerg Infect Dis 1996; 2 (3): 176-82
49. Maiden MC, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002; 359 (9320): 1829-31
50. Ramsay ME, Andrews NJ, Trotter CL, et al. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003; 326 (7385): 365-6
51. Granoff DM, Gupta RK, Belshe RB, et al. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis 1998; 178 (3): 870-4
52. Perez-Trallero E, Vicente D, Montes M, et al. Positive effect of meningococcal C vaccination on serogroup replacement in Neisseria meningitidis [letter]. Lancet 2002; 360 (9337): 953
53. Borrow R, Goldblatt D, Finn A, et al. Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United Kingdom. Infect Immun 2003; 71 (10): 5549-55
54. Shepard CW, Ortega-Sanchez IR, Scott RD, et al. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics 2005; 115 (5): 1220-32
55. Meningitis Vaccine Project. Timeline [online]. Available from URL: http://www.meningvax.org/timeline.htm [Accessed 2003 Oct 22]
56. Comité sur l'immunisation du Québec (CIQ). Evaluation du cout et des avantages potentiels d'une campagne d'immunisation contre le meningocoque de serogroup C au Quebec. Quebec: Institut national de sante publique du Quebec, 2001 Jun
57. De Wals P, Erickson L. Economic analysis of the 1992-1993 mass immunization campaign against serogroup C meningococcal disease in Quebec. Vaccine 2002; 20 (21-22): 2840-4
58. De Wals P, Nguyen VH, Erickson LJ, et al. Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease. Vaccine 2004; 22 (9-10): 1233-40
59. Jackson LA, Schuchat A, Gorsky RD, et al. Should college students be vaccinated against meningococcal disease? A cost-benefit analysis. Am J Public Health 1995; 85: 843-5
60. Rancourt C, Gregoire JP, Simons W, et al. Cost-benefit model comparing two alternative immunisation programmes against serogroup C meningococcal disease: for Quebec residents aged 2 months to 20 years. Pharmacoeconomics 2003; 21 (6): 429-42
61. Round A, Palmer S. Should we be doing more to prevent group C meningococcal infection in school age children? How can we decide? J Public Health Med 1999; 21 (1): 8-13
62. Ruedin HJ, Ess S, Zimmermann HP, et al. Invasive meningococcal and pneumococcal disease in Switzerland: cost-utility analysis of different vaccine strategies. Vaccine 2003; 21: 4145-52
63. Scott RD, Meltzer MI, Erickson LJ, et al. Vaccinating first-year college students living in dormitories for meningococcal disease: an economic analysis. Am J Prev Med 2002; 23 (2): 98-105
64. Skull SA, Butler JR, Robinson P, et al. Should programmes for community-level meningococcal vaccination be considered in Australia? An economic evaluation. Int J Epidemiol 2001; 30 (3): 571-8
65. Skull SA, Butler JR. Meningococcal vaccination for adolescents? An economic evaluation in Victoria. J Paediatr Child Health 2001; 37 (5): S28-33
66. Trotter CL, Edmunds WJ. Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales. BMJ 2002; 324 (7341): 1-6
67. Welte R, van den Dobbelsteen G, Bos JM, et al. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making. Vaccine 2004; 23: 470-9
68. Trotter CL, Edmunds WJ. Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model. Med Decis Making (in press)
69. Organisation for Economic Co-operation and Development (OECD). OECD Health Data 2004 [database on CD ROM]. Paris: OECD, 2004
70. Oostenbrink R, Moll HA, Essink-Bot ML. The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison. J Clin Epidemiol 2002; 55 (8): 791-9
71. Brunson W. Campagne 2002 de vaccination contre le méningocoque C pour les enfants de moins 6 ans. Brussels: Direction generale de la sante Communaute francaise, 2001
72. Persmedeling van het kabinet van minister Mieke Vogels. Brussels: Ministerie van de Vlaamse Gemeenschap. Departement Welzijn, Volksgezondheid en Cultuur, 2003 Feb 6
73. De Wals P, Duval B, De Serres G, et al. Right decisions in public health are those based on science and expertise: the example of the control of meningococcal disease in Quebec. Med Sci (Paris) 2003; 19 (10): 1011-5
74. Robert Koch Institut. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch Institut/Juli 2003. Epidemiologisches Bulletin 2003; 32: 251-2
75. National vaccination-calendars in Northern Europe: Iceland 2002. Epinorth 2003 [online]. Available from URL: http://www.epinorth.org [Accessed 2004 Jan 5]
76. a serie). Diario Da Republica, 2005 Mar 2
77. Lieu TA, Thompson KM, Prosser LA, et al. Economic issues in vaccine economics: perspective from the USA. Expert Rev Vaccines 2002; 1 (4): 433-42
78. Health Canada. Invasive meningococcal infection: Alberta (update). Infectious Disease News Brief 2002 Mar 8
79. Health Canada. Meningococcal conjugate vaccine: Quebec. Infectious Disease News Brief 2002 Nov 1
80. Comité sur l'immunisation du Québec (CIQ). Pertinence de l'introduction du vaccin meningococcique dans le calendrier regulier d'immunisation au Quebec. Quebec: Institut national de sante publique du Quebec, 2002 Jun
81. Zwart-van Rijkom JE, Leufkens HG, Busschbach JJ, et al. Differences in attitudes, knowledge and use of economic evaluations in decision-making in The Netherlands. The Dutch results from the EUROMET Project. Pharmacoeconomics 2000; 18 (2): 149-60
82. Salleras L, Dominguez A, Cardenosa N. Dramatic decline of serogroup C meningococcal disease in Catalonia (Spain) after a mass vaccination campaign with meningococcal C conjugated vaccine. Vaccine 2003; 21 (7-8): 729-33
83. Salleras L, Dominguez A, Cardenosa N. Impact of mass vaccination with polysaccharide conjugate vaccine against serogroup C meningococcal disease in Spain. Vaccine 2003; 21 (7-8): 725-8
84. Bundesamt für Gesundheit. Impfung gegen Meningokokken der Gruppe C. Stellungsnahme des Bundesamtes für Gesundheit und der Schweizerischen Kommission für Impffragen. Bulletin BAG 2001; 37 (1): 676-7
85. Richmond P, Borrow R, Miller E, et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 1999; 179 (6): 1569-72
86. Dobson F. My pride and joy. Daily Telegraph 2001 Jan 5
87. Salisbury DM, Beverley PC, Miller E. Vaccine programmes and policies. Br Med Bull 2002; 62: 201-11
88. Beutels P, Van Doorslaer E, Van Damme P, et al. Methodological issues and new developments in the economic evaluation of vaccines. Expert Rev Vaccines 2003; 2 (5): 649-60
89. Bos JM, Rumke H, Welte R, et al. Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands. Clin Ther 2003; 25 (10): 2614-30
90. Mansoor O, Shin S, Maher C, et al. Assessing new vaccines for national immunisation programmes. Manila: WHO Regional Office for the Western Pacific, 2000
91. National Institutes of Health. Disease Control Priorities in Developing Countries, second edition (DCP-2). In: Disease Control Priorities Project (DCPP), Fogarty International Center, National Institutes of Health, 2003 [online]. Available from URL: http://www.fic.nih.gov/dcpp/dcp2.html [Accessed 2003 Oct 22]
92. Institute of Medicine Committee to Study Priorities for Vaccine Development. In: Stratton KR, Durch JS, Lawrence RS, editors. Vaccines for the 21st Century. Washington, DC: National Academy Press, 2000
93. Van der Zeijst BAM, Dijkman MI, Kramers PGN, et al. Naar en vaccinatieprogramma voor Nederland in de 21ste eeuw. Bilthoven: National Institute of Public Health and the Environment, 2000
94. Kuntz MK, Weinstein MC. Modelling in economic evaluation. In: Drummond M, McGuire MA, editors. Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press, 2001
95. Brennan A, Akehurst R. Modelling in health economic evaluation: what is its place? What is its value? Pharmacoeconomics 2000; 17 (5): 445-59